Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial

被引：0

作者：

Gladman, Dafna D. ^{[1
]}

Rigby, William ^{[2
]}

Azevedo, Valderilio F. ^{[3
,4
,5
]}

Behrens, Frank ^{[6
]}

Blanco, Ricardo ^{[7
]}

Kaszuba, Andrzej ^{[8
]}

Kudlacz, Elizabeth ^{[9
]}

Wang, Cunshan ^{[9
]}

Menon, Sujatha ^{[9
]}

Hendrikx, Thijs ^{[10
]}

Kanik, Keith S. ^{[9
]}

机构：

[1] Univ Toronto, Toronto, ON, Canada

[2] Dartmouth Hitchcock Med Ctr, Rheumatol, Lebanon, NH 03766 USA

[3] Univ Fed Parana, Curitiba, Parana, Brazil

[4] Edumed Hlth Res Ctr, Curitiba, Parana, Brazil

[5] Biotech, Curitiba, Parana, Brazil

[6] Goethe Univ Frankfurt, Frankfurt, Germany

[7] Hosp Univ Marques de Valdecilla, IDIVAL, Rheumatol, Santander, Spain

[8] Specialstyczne Gabinety Lerkarskie DERMED, Lodz, Poland

[9] Pfizer Inc, Groton, CT 06340 USA

[10] Pfizer Inc, Collegeville, PA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

10L

引用

页数：5

共 50 条

[41] Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial
Lu Liang-Jing
Teng Jia-Lin
Bao Chun-De
Han Xing-Hai
Sun Ling-Yun
Xu Jiang-Hua
Li Xing-Fu
Wu Hua-Xiang
CHINESE MEDICAL JOURNAL, 2008, 121 (07) : 615 - 619
[42] Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
Ritchlin, Christopher T.
Deodhar, Atul
Boehncke, Wolf-Henning
Soriano, Enrique R.
Kollmeier, Alexa P.
Xu, Xie L.
Zazzetti, Federico
Shawi, May
Jiang, Yusang
Sheng, Shihong
Helliwell, Philip S.
ACR OPEN RHEUMATOLOGY, 2023, 5 (03) : 149 - 164
[43] Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial
Hara, Masako
Ishiguro, Naoki
Katayama, Kou
Kondo, Masakazu
Sumida, Takayuki
Mimori, Tsuneyo
Soen, Satoshi
Nagai, Kota
Yamaguchi, Tomonobu
Yamamoto, Kazuhiko
MODERN RHEUMATOLOGY, 2014, 24 (03) : 410 - 418
[44] Rapid Onset of Response Observed with Certolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Bi, Liqi
Li, Yuhui
He, Lan
Xu, Huji
Gu, Jieruo
Wang, Guochun
Zhang, Zhiyi
Liu, Yi
Boehnlein, Marion
Dunkel, Jochen
Shao, Jing
Harris, Kristina
Li, Zhanguo
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[45] Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
Mease, PJ
Gladman, DD
Ritchlin, CT
Ruderman, EM
Steinfeld, SD
Choy, EHS
Sharp, JT
Ory, PA
Perdok, RJ
Weinberg, MA
ARTHRITIS AND RHEUMATISM, 2005, 52 (10): : 3279 - 3289
[46] EFFICACY AND SAFETY OF GUSELKUMAB TN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY
Coates, Laura C.
Gossec, Laure
Theander, Elke
Bergmans, Paul
Neuhold, Marlies
Karyekar, Chetan S.
Shawi, May
Noel, Wim
Schett, Georg
McInnes, Iain B.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S106 - S107
[47] EFFICACY AND SAFETY OF LEVILIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS: PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL
Mazurov, V.
Korolev, M.
Kundzer, A.
Soroka, N.
Kastanayan, A.
Povarova, T.
Plaksina, T.
Antipova, O.
Kretchikova, D.
Smakotina, S.
Tciupa, O.
Raskina, T.
Kropotina, T.
Nesmeyanova, O.
Popova, T.
Dokukina, E.
Plotnikova, A.
Lutskii, A.
Zinkina-Orihan, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 550 - 551
[48] Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Mease, Philip
Deodhar, Atul
van der Heijde, Desiree
Behrens, Frank
Kivitz, Alan
Lehman, Tom
Wei, Lan
Nys, Marleen
Banerjee, Subhashis
Nowak, Miroslawa
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3798 - 3800
[49] Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial
Genovese, M. C.
Kinnman, N.
de La Bourdonnaye, G.
Rossi, C. Pena
Tak, P. P.
ARTHRITIS AND RHEUMATISM, 2011, 63 (07): : 1793 - 1803
[50] Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Patients: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Zhang, Xiao
Xu, Huji
Zhang, Zhiyi
Li, Yang
Pauer, Lynne
Liao, Shanmei
Xu, Gaiping
Zhang, Fengchun
ARTHRITIS & RHEUMATOLOGY, 2017, 69

← 1 2 3 4 5 →